{"filing":{"accession_number":"0001171843-26-004863","cik":"0001628808","ticker":"PROF","company_name":"Profound Medical Corp.","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-24","primary_document":"f8k_072426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326004863/f8k_072426.htm"},"events":[{"id":20362,"run_id":18334,"accession_number":"0001171843-26-004863","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Profound Medical announced positive clinical trial data from the Level 1 post-market CAPTAIN randomized controlled trial showing the TULSA Procedure demonstrated statistically significant superior penile length preservation compared to robotic radical prostatectomy. This is a material operational/clinical milestone for a medical device company—favorable trial results support the competitive positioning and commercial viability of the company's flagship TULSA-PRO platform. While not a traditional earnings release, restatement, or M\u0026A event, the disclosure of significant clinical efficacy data is material to investors assessing the company's product performance and market opportunity.","company_name":"Profound Medical Corp.","ticker":"PROF","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19698,"accession_number":"0001171843-26-004863","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Profound Medical announced positive clinical trial data from the Level 1 post-market CAPTAIN randomized controlled trial showing the TULSA Procedure demonstrated statistically significant superior penile length preservation compared to robotic radical prostatectomy. This is a material operational/clinical milestone for a medical device company—favorable trial results support the competitive positioning and commercial viability of the company's flagship TULSA-PRO platform. While not a traditional earnings release, restatement, or M\u0026A event, the disclosure of significant clinical efficacy data is material to investors assessing the company's product performance and market opportunity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T16:02:38.239073+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19698,"accession_number":"0001171843-26-004863","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Profound Medical announced positive clinical trial data from the Level 1 post-market CAPTAIN randomized controlled trial showing the TULSA Procedure demonstrated statistically significant superior penile length preservation compared to robotic radical prostatectomy. This is a material operational/clinical milestone for a medical device company—favorable trial results support the competitive positioning and commercial viability of the company's flagship TULSA-PRO platform. While not a traditional earnings release, restatement, or M\u0026A event, the disclosure of significant clinical efficacy data is material to investors assessing the company's product performance and market opportunity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T16:02:38.239073+00:00","company_name":"Profound Medical Corp.","ticker":"PROF","filing_date":"2026-07-24"}]}